Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FT836 + daratumumab
- Development stage
- Phase 1
- Lead developer
- Fate Therapeutics
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
FT836 + daratumumab is an investigational combination regimen being developed for the treatment of relapsed and/or refractory multiple myeloma. The regimen combines FT836, an off-the-shelf, allogeneic chimeric antigen receptor (CAR) T-cell therapy derived from a multiplexed-engineered induced pluripotent stem cell (iPSC) master cell bank, with daratumumab, an FDA-approved anti-CD38 monoclonal antibody. FT836 is engineered to target the conserved α3 domain of the stress-induced ligands MICA and MICB, which are highly expressed on multiple myeloma cells, thereby preventing proteolytic shedding and tumor escape. Additionally, FT836 incorporates a high-affinity, non-cleavable CD16a receptor (hnCD16) to enable antibody-dependent cellular cytotoxicity (ADCC) when combined with therapeutic antibodies like daratumumab, and features 'Sword & Shield' technology (alloimmune defense receptor and CD58 knockout) to evade host immune rejection without the need for conditioning chemotherapy. The combination is being evaluated in a Phase 1 investigator-initiated clinical trial.
- Other names
- daratumumab + FT836
Beyond the preview
Go deeper on FT836 + daratumumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FT836 + daratumumab.